240 related articles for article (PubMed ID: 19705973)
1. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
Bruyand M; Thiébaut R; Lawson-Ayayi S; Joly P; Sasco AJ; Mercié P; Pellegrin JL; Neau D; Dabis F; Morlat P; Chêne G; Bonnet F;
Clin Infect Dis; 2009 Oct; 49(7):1109-16. PubMed ID: 19705973
[TBL] [Abstract][Full Text] [Related]
2. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
3. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008.
Bruyand M; Dabis F; Vandenhende MA; Lazaro E; Neau D; Leleux O; Geffard S; Morlat P; Chêne G; Bonnet F
J Hepatol; 2011 Nov; 55(5):1058-62. PubMed ID: 21354449
[TBL] [Abstract][Full Text] [Related]
4. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007.
Bénard A; Mercié P; Alioum A; Bonnet F; Lazaro E; Dupon M; Neau D; Dabis F; Chêne G;
PLoS One; 2010 Jan; 5(1):e8896. PubMed ID: 20126646
[TBL] [Abstract][Full Text] [Related]
5. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study.
Ferry T; Raffi F; Collin-Filleul F; Dupon M; Dellamonica P; Waldner A; Strady C; Chêne G; Leport C; Moing VL;
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):407-15. PubMed ID: 19474755
[TBL] [Abstract][Full Text] [Related]
6. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
Lewden C; Raffi F; Cuzin L; Cailleton V; Vildé JL; Chêne G; Allavena C; Salamon R; Leport C
J Infect Dis; 2002 Sep; 186(5):710-4. PubMed ID: 12195361
[TBL] [Abstract][Full Text] [Related]
8. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P;
HIV Med; 2019 Mar; 20(3):202-213. PubMed ID: 30688008
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000-2012.
Collin A; Le Marec F; Vandenhende MA; Lazaro E; Duffau P; Cazanave C; Gérard Y; Dabis F; Bruyand M; Bonnet F;
PLoS One; 2016; 11(4):e0152970. PubMed ID: 27050752
[TBL] [Abstract][Full Text] [Related]
10. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
Zhang S; van Sighem A; Kesselring A; Gras L; Prins JM; Hassink E; Kauffmann R; Richter C; de Wolf F; Reiss P;
HIV Med; 2015 May; 16(5):265-72. PubMed ID: 25604160
[TBL] [Abstract][Full Text] [Related]
11. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
[TBL] [Abstract][Full Text] [Related]
12. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
[TBL] [Abstract][Full Text] [Related]
13. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
Monforte Ad; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law M; De Wit S; Friis-Møller N; Phillips AN; Sabin CA; Lundgren JD;
AIDS; 2008 Oct; 22(16):2143-53. PubMed ID: 18832878
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.
Matheron S; Pueyo S; Damond F; Simon F; Leprêtre A; Campa P; Salamon R; Chêne G; Brun-Vezinet F;
AIDS; 2003 Dec; 17(18):2593-601. PubMed ID: 14685053
[TBL] [Abstract][Full Text] [Related]
15. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI
AIDS; 2007 Sep; 21(14):1957-63. PubMed ID: 17721103
[TBL] [Abstract][Full Text] [Related]
16. Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Morlat P; Marimoutou C; Dequae-Merchadou L; Pellegrin I; Mercié P; Neau D; Beylot J; Dabis F
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):255-60. PubMed ID: 10839661
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
18. Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.
Chammartin F; Mocroft A; Egle A; Zangerle R; Smith C; Mussini C; Wit F; Vehreschild JJ; d'Arminio Monforte A; Castagna A; Bailly L; Bogner J; de Wit S; Matulionyte R; Law M; Svedhem V; Tallada J; Garges HP; Marongiu A; Borges ÁH; Jaschinski N; Neesgaard B; Ryom L; Bucher HC;
Clin Infect Dis; 2024 Apr; 78(4):995-1004. PubMed ID: 38092042
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells.
Lécuroux C; Girault I; Boutboul F; Urrutia A; Goujard C; Meyer L; Lambotte O; Chaix ML; Martinez V; Autran B; Sinet M; Venet A; ; ;
AIDS; 2009 Aug; 23(13):1649-58. PubMed ID: 19617814
[TBL] [Abstract][Full Text] [Related]
20. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.
Zhang S; van Sighem A; Kesselring A; Gras L; Smit C; Prins JM; Kauffmann R; Richter C; de Wolf F; Reiss P
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):265-72. PubMed ID: 22531756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
